Amount Raised
$32 Million
Round Type
Series A
RosevilleBiotechnologyDescription
Avivomed, Inc., a privately held, development stage, medical device company, announced the completion of a Series A Preferred Stock financing of $32 million. A world-class syndicate of experienced medical device investors participated in the financing. The proceeds of the Series A financing will provide the resources to enable the company to pursue the development and commercialization of innovative neuromodulation technology platforms to treat large patient populations suffering from chronic diseases.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Avivomed that raised within 45 days of this round, from Fundz verified event records.
- Arda Therapeutics raised $7.5M on January 14, 2022.
- Co-Diagnostics, Inc. raised $47M on January 14, 2022.
- DermBiont raised $33M (Seed) on January 14, 2022.
- PostEra Inc. raised $26M on January 14, 2022.
- Alterome Therapeutics, Inc. raised $64M on January 14, 2022.
- Qualia Oto, Inc. raised $1.4M (Seed) on January 14, 2022.
Who to call at Avivomed, and when
A new round usually means Avivomed is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Avivomed raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Avivomed, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Avivomed. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Avivomed raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAvivomed raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.